Approval Status
Approved October 2001

Treatment for
Female contraception

Pregnancy & Gynecology

NuvaRing is the first monthly vaginal ring approved for birth control. It is a flexible, transparent ring that provides month-long contraceptive protection through the continuous release of estrogen and progestin over a 21 day period of use.

NuvaRing conveniently fits into a woman's active lifestyle. It is simply inserted once a month, removing any daily worries over birth control. As exact positioning is not critical, NuvaRing cannot be inserted incorrectly.

As with use of other combination hormonal contraceptives, women using NuvaRing are strongly advised against smoking.

Approval of NuvaRing is based on positive results from two larger clinical trials conducted worldwide with 2,322 women who were exposed to 23,289 cycles of NuvaRing. Pregnancy rates were between one and two percent.

Adverse events associated with the use of NuvaRing may include (but are not limited to) the following:

  • Vaginitis
  • Headache
  • Upper respiratory tract infection
  • Leukorrhea
  • Sinusitis
  • Weight gain
  • Nausea

NuvaRing releases a continuous low dose of ethinyl estadiol, an estrogen, and etonogestrel, a progestin. Combination contraceptives work through the suppression of gonadotropins. Their primary function is the inhibition of ovulation; such contraceptives also alter the cervical mucus, which increases the difficulty of sperm entry to the uterus. Progesterone also makes the endometrium less favorable for implantation.

For additional information on Nuvaring, please visit Nuvaring.

NuvaRing Drug Information

The NuvaRing drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top